Tokio Marine Asset Management Co. Ltd. Has $438,000 Position in Quest Diagnostics Incorporated (NYSE:DGX)

Tokio Marine Asset Management Co. Ltd. increased its holdings in shares of Quest Diagnostics Incorporated (NYSE:DGXFree Report) by 45.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 3,294 shares of the medical research company’s stock after buying an additional 1,032 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Quest Diagnostics were worth $438,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Altshuler Shaham Ltd bought a new stake in shares of Quest Diagnostics in the fourth quarter worth $26,000. VisionPoint Advisory Group LLC grew its position in shares of Quest Diagnostics by 100.0% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock valued at $27,000 after buying an additional 109 shares during the last quarter. BKM Wealth Management LLC acquired a new stake in shares of Quest Diagnostics in the fourth quarter valued at about $29,000. Spartan Planning & Wealth Management bought a new position in shares of Quest Diagnostics during the fourth quarter worth about $31,000. Finally, Alaska Permanent Fund Corp lifted its stake in shares of Quest Diagnostics by 79.3% in the fourth quarter. Alaska Permanent Fund Corp now owns 242 shares of the medical research company’s stock worth $33,000 after acquiring an additional 107 shares during the period. 88.06% of the stock is owned by institutional investors.

Quest Diagnostics Stock Performance

NYSE DGX opened at $138.94 on Tuesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.89 and a current ratio of 0.97. The company has a market capitalization of $15.43 billion, a PE ratio of 18.70, a price-to-earnings-growth ratio of 3.05 and a beta of 0.89. Quest Diagnostics Incorporated has a 52-week low of $119.59 and a 52-week high of $145.62. The company has a 50-day simple moving average of $139.51 and a 200 day simple moving average of $133.86.

Quest Diagnostics (NYSE:DGXGet Free Report) last announced its earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.86 by $0.18. Quest Diagnostics had a net margin of 9.11% and a return on equity of 15.52%. The company had revenue of $2.37 billion during the quarter, compared to analyst estimates of $2.29 billion. During the same period in the previous year, the business earned $2.04 earnings per share. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. On average, research analysts predict that Quest Diagnostics Incorporated will post 8.79 EPS for the current year.

Quest Diagnostics Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 22nd. Shareholders of record on Monday, July 8th will be given a dividend of $0.75 per share. This represents a $3.00 dividend on an annualized basis and a yield of 2.16%. The ex-dividend date is Monday, July 8th. Quest Diagnostics’s payout ratio is currently 40.38%.

Insiders Place Their Bets

In related news, SVP Karthik Kuppusamy sold 1,760 shares of the stock in a transaction on Monday, April 29th. The shares were sold at an average price of $140.00, for a total transaction of $246,400.00. Following the transaction, the senior vice president now owns 13,435 shares of the company’s stock, valued at approximately $1,880,900. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders own 0.79% of the company’s stock.

Wall Street Analyst Weigh In

DGX has been the subject of several research analyst reports. Mizuho lifted their price objective on Quest Diagnostics from $150.00 to $155.00 and gave the stock a “buy” rating in a research report on Wednesday, April 24th. JPMorgan Chase & Co. increased their price objective on shares of Quest Diagnostics from $152.00 to $155.00 and gave the stock a “neutral” rating in a research report on Thursday, May 30th. StockNews.com lowered Quest Diagnostics from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. Truist Financial increased their price target on Quest Diagnostics from $145.00 to $150.00 and gave the stock a “hold” rating in a report on Wednesday, April 24th. Finally, Robert W. Baird increased their target price on Quest Diagnostics from $145.00 to $153.00 and gave the stock a “neutral” rating in a report on Friday. Eleven analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $147.15.

Read Our Latest Analysis on Quest Diagnostics

Quest Diagnostics Company Profile

(Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Recommended Stories

Want to see what other hedge funds are holding DGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Quest Diagnostics Incorporated (NYSE:DGXFree Report).

Institutional Ownership by Quarter for Quest Diagnostics (NYSE:DGX)

Receive News & Ratings for Quest Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quest Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.